Answers are grounded in this paper and cite their sources.
Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by a high risk of recurrence and metastasis and a lack of effective molecularly targeted therapies. Dysregulated apoptosis and autophagy contribute to TNBC progression and therapeutic resistance, while the p53/AMPK/mTOR signaling axis plays a pivotal role in coordinating cell fate and autophagic activity. Shenqi Xiaoyan Formula (SQXYF), a traditional Chinese medicine formula, has demonstrated antitumor activity; however, the mechanisms underlying its effects against TNBC remain incompletely understood. Objective This study aimed to evaluate the antitumor effects of SQXYF against TNBC and to elucidate its potential mechanisms using serum pharmacochemistry, transcriptomic profiling, and molecular validation. Methods The chemical profiles of SQXYF-containing serum were characterized by ultra-high-performance liquid chromatography–high-resolution mass spectrometry (UHPLC-HRMS). MDA-MB-231 and BT549 xenograft models were established to evaluate the in vivo antitumor effects of SQXYF. In vitro , TNBC cells were treated with SQXYF-containing serum, and cell proliferation, migration, and invasion were assessed. RNA sequencing (RNA-seq) was performed to identify potential signaling pathways involved in the effects of SQXYF. Apoptosis, autophagy, and p53/AMPK/mTOR signaling were subsequently evaluated using flow cytometry, TUNEL staining, transmission electron microscopy, immunofluorescence, Western blotting, and RT-qPCR. p53 knockdown using siRNA was further employed to validate its role in the effects of SQXYF. Results UHPLC-HRMS characterized the chemical profiles of SQXYF-containing serum. SQXYF reduced tumor growth in MDA-MB-231 and BT549 xenograft models, while SQXYF-containing serum decreased TNBC cell viability, wound closure, and Transwell invasion-associated cell counts in a concentration-dependent manner. RNA-seq analysis identified differentially expressed genes enriched in extracellular matrix–receptor interactions, metabolic processes, and mTOR-related signaling. SQXYF treatment was associated with increased apoptosis, elevated phosphorylation of p53 and AMPK, increased p21 expression, and reduced MDM2 and phosphorylated mTOR levels. Alterations in autophagy-related markers, including increased LC3B, Beclin-1, and ATG5 expression and decreased p62 expression, were also observed. In p53 knockdown experiments, several SQXYF-associated changes in AMPK/mTOR signaling and autophagy-related protein expression were attenuated, suggesting a potential involvement of p53-associated signaling without establishing a direct causal relationship. Additional analyses of xenograft tissues revealed corresponding changes in p53/AMPK/mTOR signaling, cleaved caspase-3, and autophagy-related protein expression in vivo . Conclusion SQXYF suppresses TNBC xenograft growth and reduces TNBC cell viability in vitro , accompanied by apoptosis-related and autophagy-related alterations and changes in p53-associated and AMPK/mTOR signaling. These findings provide preliminary experimental evidence for the antitumor potential of SQXYF, although further mechanistic studies are required to establish the causal contributions of these signaling pathways and clarify their relationship with autophagic flux.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: